Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US-9879061-B2 · Jan 30, 2018 · US
Antifibrotic activity of GAS6 inhibitor
US10876176B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10876176-B2 |
| Application number | US-201515535995-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2015 |
| Priority date | Dec 18, 2014 |
| Publication date | Dec 29, 2020 |
| Grant date | Dec 29, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of reducing fibrosis associated with pancreatic cancer, the method comprising: detecting the presence of fibrosis in the pancreatic cancer, and then administering to a human patient with pancreatic cancer-associated fibrosis an inhibitor of GAS6, wherein the inhibitor is a soluble AXL variant polypeptide, wherein said soluble AXL variant polypeptide: lacks the AXL transmembrane domain, lacks a functional fibronectin (FN) domain, has an Ig1 domain, and an Ig2 domain, and comprises a set of amino add substitutions relative to SEQ ID NO:1 selected from Gly32Ser, Asp87Gly, Val92Ala, and Gly127Arg or from Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg; to thereby reduce the pancreatic cancer-associated fibrosis. 2. The method of claim 1 wherein the patient has been treated with gemcitabine. 3. The method of claim 1 wherein the soluble AXL variant polypeptide further comprises an Fc domain linked to the AXL variant polypeptide by a linker comprising from 1 to 5 (GLS) 4 SER (SEQ ID NO:10) units. 4. The method of claim 1 wherein the soluble AXL variant polypeptide further comprises a conjugated polymer selected from polyethylene glycol (PEG), a PEG-containing polymer, a degradable polymer, a biocompatible polymer, or a hydrogel.
Assignees
Inventors
Classifications
- A61K38/45Primary
Transferases (2) · CPC title
- C12Y207/10001Primary
Receptor protein-tyrosine kinase (2.7.10.1) · CPC title
from animals; from humans {(enzyme inhibitors A61K38/005)} · CPC title
Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10876176B2 cover?
- Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
- Who is the assignee on this patent?
- Aravive Biologics Inc, Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification A61K38/45. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).